vilobelimab
General
Pronunciation:
vil-oh-bel-i-mab
Trade Name(s)
- Gohibic
Ther. Class.
Pharm. Class.
complement inhibitors
monoclonal antibodies
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., and Cynthia A. Sanoski. "Vilobelimab." Davis's Drug Guide, 20th ed., F.A. Davis Company, 2026. Nursing Central, nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/3580109/11/vilobelimab.
Vallerand AHA, Sanoski CAC. Vilobelimab. Davis's Drug Guide. F.A. Davis Company; 2026. https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/3580109/11/vilobelimab. Accessed June 26, 2026.
Vallerand, A. H., & Sanoski, C. A. (2026). Vilobelimab. In Davis's Drug Guide (20th ed.). F.A. Davis Company. https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/3580109/11/vilobelimab
Vallerand AHA, Sanoski CAC. Vilobelimab [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2026. [cited 2026 June 26]. Available from: https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/3580109/11/vilobelimab.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - vilobelimab
ID - 3580109
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
BT - Davis's Drug Guide
UR - https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/3580109/11/vilobelimab
PB - F.A. Davis Company
ET - 20
DB - Nursing Central
DP - Unbound Medicine
ER -

Davis's Drug Guide

